Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
4
×
boston blog main
indiana blog main
indiana top stories
life sciences
national blog main
national top stories
san francisco blog main
san francisco top stories
wisconsin blog main
4
×
wisconsin top stories
boston top stories
boulder/denver blog main
boulder/denver top stories
clinical trials
detroit blog main
detroit top stories
fda
national
new york blog main
new york top stories
novartis
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
biogen
cancer
deals
deerfield management
eli lilly
europe blog main
europe top stories
gilead sciences
ipo
melinta therapeutics
What
medicines
4
×
bio
covid
deal
fda
gets
ipo
new
roundup
abandoning
acquisitions
activity
ago
amgen
announced
approval
approvals
baggage
biogen
candidates
ceo
clamped
class
collabs
companies
cuts
daniel
delays
developed
developing
development
dicerna
drug
economic
fast
free
gilead
gilead’s
head
help
Language
unset
Current search:
medicines
×
" wisconsin blog main "
×
biotech
×
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
5 years ago
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines